Anil Duggal

846 total citations
27 papers, 452 citations indexed

About

Anil Duggal is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Anil Duggal has authored 27 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 10 papers in Cardiology and Cardiovascular Medicine and 7 papers in Internal Medicine. Recurrent topics in Anil Duggal's work include Cardiac Arrhythmias and Treatments (8 papers), Atrial Fibrillation Management and Outcomes (7 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Anil Duggal is often cited by papers focused on Cardiac Arrhythmias and Treatments (8 papers), Atrial Fibrillation Management and Outcomes (7 papers) and Venous Thromboembolism Diagnosis and Management (7 papers). Anil Duggal collaborates with scholars based in United States, Canada and Netherlands. Anil Duggal's co-authors include Michele Mercuri, Sabina A. Murphy, Eugene Braunwald, Robert P. Giugliano, Elliott M. Antman, Christian T. Ruff, Christina Fanola, M. Angelyn Bethel, James Jin and Steven M. Haffner and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Cancer.

In The Last Decade

Anil Duggal

25 papers receiving 439 citations

Peers

Countries citing papers authored by Anil Duggal

Since Specialization

Citations

This map shows the geographic impact of Anil Duggal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anil Duggal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anil Duggal more than expected).

Fields of papers citing papers by Anil Duggal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anil Duggal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anil Duggal. The network helps show where Anil Duggal may publish in the future.

Co-authorship network of co-authors of Anil Duggal

This figure shows the co-authorship network connecting the top 25 collaborators of Anil Duggal. A scholar is included among the top collaborators of Anil Duggal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anil Duggal. Anil Duggal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE‐TAVI AF Trial 2025 ·Journal of the American Heart Association ·George Dangas, Martin Unverdorben, Johny Nicolas, Christian Hengstenberg, (unknown), Helge Möllmann, James Jin, Fayaz A. Shawl, Masanori Yamamoto, Shigeru Saito, Rainer Hambrecht, Anil Duggal, Nicolas M. Van Mieghem	0
2	Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Hamim Zahir, Anil Duggal, (unknown), James Jin, Tarek A. Leil	1
3	Sex Differences Among Patients Receiving Edoxaban vs Vitamin K Antagonist for Atrial Fibrillation After TAVR 2023 ·JACC Advances ·Roxana Mehran, Alessandro Spirito, James Jin, Cathy Chen, Julia Seeger, Julia Mascherbauer, Pascal Vranckx, Raúl Moreno, Iréne Lang, Anil Duggal, Yusuke Watanabe, Piera Capranzano, Annapoorna Kini, Verena Veulemans, Elena Tessitore, Kentaro Hayashida, Martin Unverdorben, Nicolas M. Van Mieghem, Christian Hengstenberg, George Dangas	0
4	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban 2021 ·Journal of Thrombosis and Haemostasis ·Floris T.M. Bosch, Frits I. Mulder, Menno V. Huisman, Jeffrey I. Zwicker, Marcello Di Nisio, Marc Carrier, Annelise Segers, Peter Verhamme, Saskia Middeldorp, Jeffrey I. Weitz, Michael Grosso, Anil Duggal, Harry R. Büller, Tzu‐Fei Wang, (unknown), Pieter W. Kamphuisen, Gary E. Raskob, Nick van Es	12
5	ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism 2021 ·Cardiology in the Young ·(unknown), Michael A. Portman, Felix Berger, Jeffrey P. Jacobs, Jane W. Newburger, Anil Duggal, Michael Grosso, (unknown), (unknown), Neil A. Goldenberg	10
6	The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease 2020 ·Research and Practice in Thrombosis and Haemostasis ·C. Heleen van Ommen, Manuela Albisetti, Anthony K.C. Chan, Jeremie H. Estepp, Julie Jaffray, Gili Kenet, Guy Young, (unknown), Michael Grosso, Anil Duggal	24
7	Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial 2018 ·Journal of the American Heart Association ·Christina Fanola, Christian T. Ruff, Sabina A. Murphy, James Jin, Anil Duggal, (unknown), Piyamitr Sritara, Michele Mercuri, Pieter W. Kamphuisen, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano	108
8	EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL 2017 ·Journal of the American College of Cardiology ·Christina Fanola, Christian T. Ruff, Sabina A. Murphy, James Jin, Anil Duggal, Michele Mercuri, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano	6
9	An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults 2017 ·Clinical Pharmacokinetics ·Kenneth L. Duchin, Anil Duggal, George Atiee, (unknown), (unknown), (unknown), Ling He, George Zhang, Tarundeep Kakkar	13
10	International Interdisciplinary Rhytidectomy Survey 2010 ·Annals of Plastic Surgery ·D Heath Stacey, Jeremy P. Warner, Anil Duggal, K.A. Gutowski, Benjamin C. Marcus	10
11	Utility Scores for Facial Disfigurement Requiring Facial Transplantation [Outcomes Article] 2010 ·Plastic & Reconstructive Surgery ·Hani Sinno, Stéphanie Thibaudeau, Anil Duggal, Lucie Lessard	32
12	Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial 2008 ·American Heart Journal ·Robert M. Califf, Mitradev Boolell, Steven M. Haffner, M. Angelyn Bethel, John J.V. McMurray, Anil Duggal, Rury R. Holman	67
13	Pathological reporting of colorectal cancer specimens: a retrospective survey in an academic Canadian pathology department. 2008 ·PubMed ·Nancy Chan, Anil Duggal, Michele M. Weir, David K. Driman	22
14	Toxic shock syndrome in an adult burn patient 2007 ·Burns ·(unknown), Anil Duggal, (unknown), Edward E. Tredget	4
15	A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan 2004 ·Cancer Chemotherapy and Pharmacology ·Claire F. Verschraegen, Andrzej P. Kudelka, Wei Hu, (unknown), (unknown), Evelyne M. Loyer, (unknown), Anil Duggal, Robert De Jager	1
16	Reconstructing Tumour Defects: Lyophilised, Irradiated Bone Allografts 2003 ·Cell and Tissue Banking ·(unknown), Manish Agarwal, Ajay Puri, (unknown), Anil Duggal	9
17	Fibroblastic Osteosarcoma Arising in Chronic Osteomyelitis 2003 ·Clinical Radiology ·Ajay Puri, (unknown), (unknown), Anil Duggal, Manish Agarwal	10
18	A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan 2003 ·Cancer Chemotherapy and Pharmacology ·Claire F. Verschraegen, Andrzej P. Kudelka, Wei Hu, (unknown), John J. Kavanagh, Evelyne M. Loyer, (unknown), Anil Duggal, Robert De Jager	13
19	The Use of Irradiated Allografts in Reconstruction of Tumor Defects – the Tata Memorial Hospital Experience 2003 ·Cell and Tissue Banking ·(unknown), Manish Agarwal, Ajay Puri, (unknown), Anil Duggal	8
20	A Phase II study of intravenous exatecan mesylate (DX‐8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma 2003 ·Cancer ·Francisco J. Esteva, Edgardo Rivera, Massimo Cristofanilli, Vicente Valero, Melanie Royce, Anil Duggal, (unknown), (unknown), Gabriel N. Hortobágyi	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact